SCHEMBL5855310

SCHEMBL5855310

Oc1ccc(C2COc3cc(O)ccc3C2CCCCCCCCCSCCCC(F)(F)C(F)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 11/20 0.39
ESR2 Q92731 9/20 0.39
SHBG P04278 1/20 0.34
CYP3A4 P08684 2/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
NR1I2 O75469 1/20 0.33
NR3C1 P04150 1/20 0.33
PGR P06401 1/20 0.33
ESRRA P11474 1/20 0.33
EPHX2 P34913 1/20 0.33
PPARG P37231 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
SIRT5 Q9NXA8 1/20 0.33
CYP1A2 P05177 1/20 0.33
ALOX15 P16050 1/20 0.33
CYP2C19 P33261 1/20 0.33
TTR P02766 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5855269 0.85 ESR1 (0.34) ESR1ESR2SHBGCYP3A4MAOA
SCHEMBL5857617 0.82 PPARG (0.33) ESR1ESR2PPARG
SCHEMBL7589244 0.81 ESR1 (0.49) ESR1ESR2PPARG
SCHEMBL7262206 0.79 ESR1 (0.37) ESR1ESR2CYP3A4MAOAMAOB
SCHEMBL7588656 0.75 ESR1 (0.36) ESR1ESR2CYP3A4NR1I2NR3C1
SCHEMBL7585889 0.75 ESR1 (0.36) ESR1ESR2CYP3A4NR1I2NR3C1
SCHEMBL10593671 0.75 ESR1 (0.43) ESR1ESR2SHBGCYP3A4NR1I2
SCHEMBL7596943 0.71 ESR1 (0.36) ESR1ESR2CYP3A4NR1I2NR3C1
SCHEMBL5854227 0.70 ESR1 (0.33) ESR1ESR2CYP3A4NR1I2NR3C1
SCHEMBL5854583 0.70 ESR1 (0.34) ESR1ESR2CYP3A4NR1I2NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074819-B2 Benzopyran or thiobenzopyran derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-07-11 US disclosed
US-20040102479-A1 Novel benzopyran or thiobenzopyran derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA 2004-05-27 US disclosed
US-6645951-B1 Antiestrogens for treating breast cancer CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-11-11 US disclosed
EP-1087959-A1 NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-04-04 EP disclosed
WO-1999065893-A1 NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES C & C RESEARCH LABORATORIES (KR) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102479-A1 Novel benzopyran or thiobenzopyran derivatives NR5A1, SHBG, ESR2 ESR1 12/4885ESR2 3/4885SHBG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.